

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 1 8 2002

TECH CENTER 1600/2900

Applicant:

Peter S. Linsley et al.

Examiner:

P. Gambel

Serial No.:

09/666,267

Group Art Unit:

1644

Filed:

September 21, 2000

Docket:

30436.11US06

Title:

LIGAND FOR CD28 RECEPTOR ON B CELLS AND METHODS

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on September 19, 2002.



55 South Lake Avenue, Suite 710 Pasadena, California 91101 September 19, 2002

Office of Initial Patent Examination's Customer Service Center Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

Transmittal Sheet in duplicate containing Certificate under 37 C.F.R. 1.8

Request for Corrected Filing Receipt

 \boxtimes Exhibits 1-2

Return Postcard

Please charge any and/or additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO

55 South Lake Avenue, Suite 710 Pasadena, California 91101 (626) 395-7801 Name: Sarah B. Adriano

Reg. No.: 34,470 Initials: SBA

Customer No. 26,941





RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OCT 1 8 2002

TECH CENTER 1600/2900

Applicants

Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle and William Brady

Serial No.

09/666,267

Examiner: P. Gambel

Filed

September 21, 2000

Group Art Unit: 1644

For

LIGAND FOR CD28 RECEPTOR ON B CELLS AND METHODS

55 South Lake Avenue, Suite 710 Pasadena, California 91101 September 19, 2002

Honorable Assistant Commissioner for Patents Washington, D.C. 20231

Sir/Madam:

REQUEST FOR CORRECTED FILING RECEIPT

Applicants are requesting correction of the records of the United States Patent and Trademark Office and issuance of a corrected filing receipt for the above-referenced patent application. The Patent Office issued a filing receipt, dated August 28, 2002, which contained an error.

The filing receipt incorrectly describes USSN 08/219,200, filed March 29, 1994 as a divisional of USSN 07/722,101, filed June 27, 1991 as a continuation of USSN 07/547,980, filed July 2, 1990. A photocopy of the filing receipt is provided herein, Exhibit 1 (one page).

An accurate filing receipt should recite that USSN 08/219,200, filed March 29, 1994 is a File-Wrapper-Continuation of USSN 07/722,101, filed June 27, 1991, as a Continuation-In-Part of USSN 07/547,980 filed July 2, 1990. Exhibit 2 (two pages) shows the correct priority data.

Request for Correction of Filing Receipt

Applicant: Linsley et al. U. S. Serial No.: 09/666,267 Filing date: September 21, 2000

Page: 2

う

Correction of the records of the United States Patent and Trademark Office and issuance of a corrected filing receipt are respectfully solicited.

No fee is deemed necessary in connection with the filing of this Request for Corrected Filing Receipt. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-0306.

Respectfully submitted,

Sarah B. Adriano

Registration No. 34,470

Attorney for Applicants

Mandel & Adriano


55 South Lake Avenue, Suite #710

Pasadena, California 91101

(626) 395-7801

Customer No.: 26,941

c:\trt\30436(bms)\11us06\file wrapper\corfil rec.doc



BECEIVED OCT 1 8 2002

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER

FILING DATE

GRP ART UNIT

FIL FEE REC'D

ATTY.DOCKET.NO DRAV

DRAWINGS

TOT CLAIMS | IND CLAIMS

09/666,267

09/21/2000

1644

770

30436.11US06

17

3 2

Sarah B Adriano Mandel & Adriano 35 N Arroyo Parkway Ste 60 Pasadena, CA 91103 CONFIRMATION NO. 1523
CORRECTED FILING RECEIPT
COC0000000008699340*

Date Mailed: 08/28/2002

Receipt is acknowledged of this nonprevisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Peter S. Linsley, Seattle, WA; Jeffrey A. Ledbetter, Seattle, WA; Nitin K. Damle, Renton, WA; William Brady, Bothell, WA;

Domestic Priority data as claimed by applicant

file wrapper

THIS APPLICATION IS A DIV OF 08/459,766 06/02/1995
WHICH IS A DIV OF 08/219,200 03/29/1994
WHICH IS A DIV OF 07/722,101 06/27/1991 ABN
WHICH IS A CON OF 07/547,980 07/02/1990 ABN
WHICH IS A CIP OF 07/498,949 03/26/1990 ABN

Foreign Applications

Continuation - In-Part

If Required, Foreign Filing License Granted 12/28/2000

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

SEP 9 2002

MANDEL & ADRIANO
INTELLECTUAL PROPERTY ATTORNEYS

ECH CENTER 1600/2900



Dkt. 30436.11US06 SBA/GSH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Peter S. Linsley et al.

Serial No.

09/666,267

Examiner: P. Gambel

Filed

September 21, 2000

Group Art Unit: 1644

For

LIGAND FOR CD28 RECEPTOR ON B CELLS AND METHODS

35 N. Arroyo Pkwy., Suite 60 Pasadena, California 91103 December 22, 2000

Assistant Commissioner for Patents Washington, D.C. 20231

SIR:

SECOND PRELIMINARY AMENDMENT

With the entry of this Amendment, and before the first Action in this case, please amend the subject application as follows.

In the Specification

At page 1, line 1, please replace

"This is a Divisional of application Serial No. 08/219,200, filed March 29, 1994, which is a file wrapper continuation of U.S. Serial No. 07/722,101, filed June 27, 1991, now abandoned, which was a continuation-in-part of U.S. Serial No. 547,980, filed July 2, 1990, now abandoned, which was a continuation-in-part of U.S. Serial No. 498,949, filed March 26, 1990, now abandoned, which application(s) are incorporated herein by reference."

with

Exhibit 2, page 1

Applicants: Peter S. Linsley et al.

U.S. Serial No.: 09/666,267 Filed: September 21, 2000

Page 2

--This is a divisional of U.S. Serial No. 08/459,766, filed June 2, 1995, which is a divisional of U.S. Serial No. 08/219,200, filed March 29, 1994, which is a file wrapper continuation of U.S. Serial No. 07/722,101, filed June 27, 1991, now abandoned, which was a continuation-in-part of U.S. Serial No. 07/547,980, filed July 2, 1990, now abandoned, which was a continuation-in-part of U.S. Serial No. 07/498,949, filed March 26, 1990, now abandoned, which applications are incorporated herein by reference.--

In the Claims:

Please add claims 79-88 as follows:

- --79. (new) A method for interfering with binding of a B7 antigen with a CD28 antigen comprising contacting the B7 antigen with a monoclonal antibody or fragment thereof that binds the B7 antigen.--
- --80. (new) The method of claim 79, wherein interfering with the binding of B7 antigen with CD28 antigen prevents B cell interaction with T cells.--
- --81. (new) The method of claim 79, wherein interfering with binding of the B7 antigen with the CD28 antigen reduces T cell proliferation.--
- --82. (new) The method of claim 79, wherein interfering with the binding of B7 antigen with CD28 antigen inhibits T_h-cell induced Ig production by B cells.--
- --83. (new) The method of claim 79, wherein the monoclonal antibody binds to the B7 antigen and thereby blocks CD28-mediated binding to B7 by at least approximately 30%.--

Exhibit 2, page 2